Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 7/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459149 | 0.75 | NISCH (0.41) | NISCHNPY5RALDH1A1KDM4EBACE1 | |
| SCHEMBL4479177 | 0.75 | NPY5R (0.57) | NPY5RTSHRALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL4468926 | 0.75 | MAOB (0.49) | NISCHNPY5RMAPTBACE1 | |
| SCHEMBL11827731 | 0.74 | NISCH (0.42) | NISCHNPY5RGAATSHRHPGD | |
| SCHEMBL4480647 | 0.74 | MAOB (0.48) | NISCHNPY5RTSHRALDH1A1CYP1A2 | |
| SCHEMBL4472900 | 0.73 | NPY5R (0.58) | NISCHNPY5RALDH1A1CYP1A2MAPT | |
| SCHEMBL4469985 | 0.71 | NPY5R (0.57) | NISCHNPY5RALDH1A1KDM4E | |
| SCHEMBL11013264 | 0.70 | BACE1 (0.35) | CYP1A2BACE1HTR2A | |
| SCHEMBL4474683 | 0.68 | NPY5R (0.54) | NPY5RBACE1 | |
| SCHEMBL6591928 | 0.63 | BACE1 (0.61) | NPY5RALDH1A1MAPTBACE1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-7482358-B2 | Imidazoline compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060135559-A1 | Novel imidazoline compounds | MSD K.K. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-7064142-B2 | Imidazonline compounds | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135559-A1 | Novel imidazoline compounds | GPR119, NPY1R, NPY2R | NISCH 4065/4885NPY5R 9/4885GAA 2269/4885 |
| US-20030158418-A1 | Novel imidazonline compounds | NPY1R, NPY2R, GPR119 | NISCH 3812/4885NPY5R 4/4885GAA 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.